Zargis Cleared as Apple iPhone Developer; Medical Applications for Smartphones Planned
October 21 2009 - 11:17AM
PR Newswire (US)
STAMFORD, Conn., Oct. 21 /PRNewswire/ -- Zargis Medical Corp., a
subsidiary of Speedus Corp. (NASDAQ:SPDE) and a spin-off from
Siemens Corporate Research (NYSE:SI), today announced that is has
been cleared as an Apple® iPhone® developer and has begun
development of medical diagnostic support software and related
peripherals for the iPhone and other leading smartphones. Zargis
has identified the handheld environment as a logical delivery
platform for its telemedicine and diagnostic software initiatives,
and with its team of experienced developer's plans to leverage the
smartphone platform as a mobile hub between medical device
peripherals and computer-aided diagnostic support located either
locally or remotely. A recent report released by Manhattan Research
stated that 64% of doctors, more than double the number eight years
ago, own smartphones, and that this figure will increase to 81%
penetration in 2012. However, despite the rapid adoption of the
iPhone and other smartphones by physicians, currently available
healthcare applications for these devices are generally limited to
medical reference libraries, educational tools and applications
designed to manage patient medical records. "The future of
healthcare delivery is about connectivity and mobility. Zargis'
expertise in computer-aided auscultation and our advanced medical
software platform positions us perfectly to create diagnostic
software and peripherals that are a natural fit for smartphones. We
intend to improve healthcare efficiency by helping clinicians bring
medical technology to the patient, rather than the other way
around," stated Zargis CEO John Kallassy. About Zargis Medical
Corp. Zargis Medical Corp. develops advanced diagnostic decision
support products and services for primary care physicians,
pediatricians, cardiologists and other healthcare professionals.
Zargis was formed in 2001 when Siemens Corporate Research, a
division of Siemens AG (NYSE:SI), and Speedus Corp. co-invested to
develop and market an advanced acoustic technology designed to
detect heart abnormalities identified through analysis of heart
sounds. For additional information about Zargis or Speedus Corp.,
contact Peter Hodge at 888.773.3669 (ext. 23) or or visit the
following Web sites: http://www.zargis.com/ and
http://www.speedus.com/. Statements contained herein that are not
historical facts, including but not limited to statements about the
Company's product, corporate identity and focus, may be
forward-looking statements that are subject to a variety of risks
and uncertainties. There are a number of important factors that
could cause actual results to differ materially from those
expressed in any forward-looking statements made by the Company,
including, but not limited to, the continuing development of the
Company's sales, marketing and support efforts. iPhone and Apple
are registered trademarks of Apple Inc. DATASOURCE: Zargis Medical
Corp. CONTACT: Peter Hodge, +1-888-773-3669 (ext. 23), Web Site:
http://www.zargis.com/
Copyright
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Oct 2023 to Oct 2024